Cheng Liu

CIK: 0001996255

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (33.3%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ESLA

Estrella Immunopharma, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

ESLA
Estrella Immunopharma, Inc.
Aug 25, 2026
Exercise(M)
Direct
100K shares at avg. $0.81$82K
ESLA
Estrella Immunopharma, Inc.
Oct 30, 2024
Award(A)
Incentive Share Option
Direct
490.8K shares-
ESLA
Estrella Immunopharma, Inc.
Oct 30, 2024
Award(A)
Nonstatutory Share Option
Direct
509.2K shares-

		Type	Shares	Price		Ownership
Aug 25, 2026	ESLA Estrella Immunopharma, Inc.	Exercise(M)	100,000	$0.81	$81,500	Direct
Oct 30, 2024	ESLA Estrella Immunopharma, Inc.	Award(A) Incentive Share Option	490,796	-	-	Direct
Oct 30, 2024	ESLA Estrella Immunopharma, Inc.	Award(A) Nonstatutory Share Option	509,204	-	-	Direct

1-3 of 3 transactions

About Liu Cheng

Liu Cheng (SEC CIK 0001996255) files insider reports with the SEC as CEO of Estrella Immunopharma, Inc. (ESLA).

Signal8 holds 2 ownership filings by Liu Cheng, all Form 4s, filed between Feb 14, 2025 and Aug 26, 2026. Those filings report 3 transactions, from Oct 30, 2024 to Aug 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Liu Cheng's filings is in EMERYVILLE, CA.

Recent filings by Liu Cheng

Aug 25, 2026: Option exercise of ESLA shares (Form 4, code M).
Oct 30, 2024: Grants or awards of ESLA derivative securities (2 lines, Form 4, code A).

Other insiders filing for Estrella Immunopharma, Inc. (ESLA)

Pussinen Cynthia, CEO
Xu Jiandong, Chief Financial Officer
Jia Dengyao, Director

How to read Form 4 transaction codes